Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas
NCT ID: NCT04216537
Last Updated: 2021-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
3000 participants
OBSERVATIONAL
2018-01-01
2025-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glioma Patients Registry Based on Radiological, Histopathological and Genetic Analysis
NCT04220424
Visual Study of Molecular Genotype in Glioma Evolution
NCT03750890
MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
NCT04217018
Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
NCT04217044
Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
NCT05541042
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glioma groups based on molecular pathology or genetic variation
Patients with newly diagnosed glioma that receive tumor resection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Life expectancy of greater than 3 months
* Must receive tumor resection
* Must have sufficient fresh frozen tissues for NGS
* Signed informed consent
Exclusion Criteria
* No sufficient amount of tumor tissues for detection of molecular pathology
* Patients who are pregnant or breast feeding
* Patients who are suffered from severe systematic malfunctions
* Do not have sufficient fresh frozen tissues for NGS
1 Year
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Zhengzhou University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhenyu Zhang
Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GiomaMG-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.